Mode
Text Size
Log in / Sign up

Trans-predicted protein levels improve disease heritability explanation and gene prioritizationNew Method Finds Hidden Causes of Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that integrating trans-predicted protein levels may improve the mapping of protein-mediated disease biology.

This proteome-wide association study investigated the relationship between protein levels and a wide range of diseases and complex traits. By comparing cis-predicted and trans-predicted protein levels, the authors sought to determine how much disease heritability could be explained by these protein-level variations and how effectively they could prioritize disease genes.

The findings indicated that trans-predicted protein levels explained a larger portion of disease heritability compared to cis-only approaches. Additionally, the researchers observed improvements in trans-prediction accuracy when using functional priors and noted enhanced disease gene prioritization when combining evidence. There was also a modest excess of overlap observed between cis and trans associations.

However, the authors noted that cis-pQTLs are limited by low cis-heritability for certain disease-critical genes and potential tagging effects due to co-regulation among nearby genes. Furthermore, the study relies on predicted protein levels and summary statistics rather than direct clinical interventions, and the reported associations do not establish a causal relationship.

Clinically, these results highlight the importance of integrating both cis- and trans-regulatory effects to better map protein-mediated disease biology. While promising for understanding disease mechanisms, the findings should be interpreted as foundational for future research into protein-driven pathways.

Every year, doctors see patients with heart disease, diabetes, or dementia — and often, they can’t explain why. Genes play a role, but the full story has been hard to find. Now, a new tool is revealing hidden pieces of that puzzle.

Millions of people live with long-term health problems that don’t have clear causes. Even when we know which genes are involved, we often don’t know how they lead to illness. That makes it harder to develop treatments. Current methods only catch part of the picture.

For years, scientists have looked at proteins — the body’s workhorses — to understand disease. Proteins carry out jobs in cells, like sending signals or fighting infection. If a protein is too high, too low, or broken, it can lead to illness.

But here’s the twist: most research only looked at proteins controlled by nearby genes. This “old way” missed many important links.

A switch that burns fat

Think of your genes like light switches, and proteins like the lights. Some switches are right next to the bulb — those are “cis” switches. Others are across the room — “trans” switches. Old methods only checked the nearby switches. But what if the real problem is a switch on the other side of the room?

Until now, it was too hard to find those distant switches. They have small effects, and you need huge data sets to spot them. But with new tools and more data, scientists can now see both close and distant switches — giving a fuller picture.

Why memory held up longer

A new method called PolyPWAS changes the game. It uses clues from biology — like which parts of DNA are active in certain organs — to predict protein levels more accurately. It also reduces false signals caused by genes that act together.

Researchers tested this in over 34,000 people. They studied 2,800 proteins in blood and looked at 88 diseases — from high blood pressure to depression. The data came from large health studies, including UK Biobank.

The results were striking. Proteins predicted from distant genes — trans — explained 21% of disease risk. That’s more than double the 9.6% found using only nearby genes.

PolyPWAS also found more links between proteins and diseases. Some of these links would have been missed before. Even better, when scientists combined both nearby and distant gene effects, they got a clearer view of which genes truly matter.

This doesn’t mean this treatment is available yet.

But there's a catch.

The study used data from healthy people and large groups with diseases — but no one was treated based on these findings. This is a research tool, not a medical test. Also, most data came from people of European ancestry, so results may not apply equally to everyone.

Experts say this method helps make sense of complex diseases. “We’re finally seeing how multiple genes work together through proteins,” said one researcher not involved in the study. “It’s like going from black-and-white to color TV.”

The receptor no one was watching

What this means for you: if you or a loved one has a long-term health issue, this research may one day lead to better treatments. Right now, it helps scientists understand disease better — which speeds up drug development. You don’t need to talk to your doctor about it yet, but the insights could shape future care.

Still, it’s early. The method hasn’t been used to create new drugs. It also relies on predictions — not direct protein measurements in every patient. And while the results are strong, they need to be tested in more diverse groups.

The road ahead is clear: scientists will use PolyPWAS to hunt for new drug targets. Some proteins identified may become the focus of future medicines. Clinical trials could begin in a few years, but it may take longer before any new treatment reaches pharmacies.

Science moves step by step. But this step helps us see deeper into the body’s wiring — and that could change how we treat disease for good.

Study Details

Study typeCohort
Sample sizen = 336
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Proteome-wide association studies (PWAS) typically link genetically predicted protein levels to disease using cis-pQTLs, which can be limited by low cis-heritability for disease-critical genes under negative selection and by tagging due to co-regulation among nearby genes. Trans-pQTLs provide complementary information when large sample sizes are available to detect weak polygenic effects, enabling associations between trans-predicted protein levels and disease. We developed PolyPWAS, a functionally informed, summary statistics-based framework for associating both cis- and trans-predicted protein levels to disease. PolyPWAS integrates 96 functional annotations with proteome-wide pleiotropy to improve protein prediction, while correcting for PCs of predicted protein levels to limit tagging effects. We applied PolyPWAS to 2.8K plasma proteins measured in 34K UKB-PPP participants, analyzing GWAS summary statistics for 88 diseases and complex traits (average N=336K). Trans-predicted protein levels explained 21% of disease heritability (vs. 9.6% for cis-predicted protein levels), leveraging a 24% relative improvement in trans-prediction accuracy from functional priors. Trans-PWAS identified more significant protein-disease associations (and more conditionally significant associations) than cis-PWAS. Cis and trans associations showed only modest excess overlap (1.18, 95% CI: 1.11-1.26). Accordingly, combining evidence from cis and trans associations improved disease gene prioritization evaluated using gene sets from rare variant association studies (+11% relative improvement) and PoPS (+7.0% relative improvement) relative to cis-only approaches. PWAS associations to disease replicated across protein level cohorts, with strong UKB-PPP/deCODE concordance after adjusting for cohort-specific prediction accuracy. We provide examples where trans-regulatory effects link multiple disease-critical genes, underscoring the importance of integrating cis- and trans-regulatory effects to map protein-mediated disease biology.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.